Since PPP1R1A is directly up-regulated by EWS/FLI and specifically highly expressed in ES but not the putative cell of origin, mesenchymal stem cells [3], our findings suggest a novel specific therapeutic strategy that is promising in enhancing therapeutic efficacy and improving outcome of patients with metastatic ES. This evidence concerns the gene FLII and Ewing sarcoma.